Arab Company for Pharmaceutical Products (ARABIO)/ Kingdom of Saudi Arabia
ARABIO was founded in 2007 with a capital of SAR 186,000,000, equivalent to KWD 14,508,000. ACDIMA owns 31.38% in the capital of this Company. ARABIO sales in 2014 amounted to SAR 211.7 million, with an increment at 425% as compared to the previous year. The profit of the Company for the same year amounted to SAR 3.5 million, equivalent to KWD 273,000. The main objective of the Company is manufacturing and marketing vaccines and biological products, in addition to conducting research leading to the discovery of new products. The production program consists of injection lines, liquid containers, and dried containers to produce vaccines for seasonal influenza, hepatitis and meningitis. Moreover, ARABIO targets producing other vaccines in the future, such as rotavirus, measles and other vaccines. The company’s factory was licensed, and certain products were registered at the Saudi Food and Drug Authority.